Genetics of Alzheimer's Disease
BMJ 284:1065-1066, Harris,R., 1982
Evidence For & Against the Transmissibility of Alzheimer Disease
Neurol 30:945-950, Goudsmit,J.,et al, 1980
Presenile Alzheimer Disease:Amyloid Plaques in the Cerebellum
Neurol 30:820-825, Pro,J.D.,et al, 1980
Studies in Aging of the Brain:IV. Familial Alzheimer Dis. :Relat. to Transmiss. Demetia, Aneuploidy, & Microtubular Defects
Neurol 29:1402, Book,R.H.,et al, 1979
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Rapidly Progressive Alzheimer Disease
Arch Neurol 68:1124-1130, Schmidt, C.,et al, 2011
Rapidly Progressive Neurodegenerative Dementias
Arch Neurol 66:201-207, Josephs,K.A.,et al, 2009
Progressive Aphasia with Rapidly Progressive Dementia in a 49 Year Old Woman
JNNP 66:238-243, Greene,J.D.W.,et al,, 1999
Posterior Cortical Atrophy:Neuropathologic Correlations
Arch Neurol 51:269-274, Victoroff,J.,et al, 1994
Brain Single-Photon Emission Computed Tomography
Neurol 44:1970-1977, Masdeu,J.C.,et al, 1994
Dementia Presenting with Aphasia:Clinical Characteristics
JNNP 54:542-545, Mendez,M.F.&Zander,B.A., 1991
Familial Alzheimer's Disease with Myoclonus and'Spongy Change'
Arch Neurol 45:1097-1100, Duffy,P.,et al, 1988
Alzheimer's Disease, Parkinson's Disease, & Motoneurone Disease:Abiotropic Interaction Between Ageing & Environment
Lancet 2:1067-1068, Calne,D.B.,et al, 1986
Biologic Distinction Between Sporadic & Familial Alzheimer Disease by an in vitro Cell Fusion Test
Neurol 31:323-325, Dubois-Moreau,M.C.,et al, 1981
Clinical Similarity of Alzheimer & Creutzfeldt-Jakob Disease
Ann Neurol 6:368-369, Watson,C.P., 1979
Progressive Dementia-"Aspects of Diagnosis"
Hospital Physician, Nov 1970, p. 84., , 1970
Encephalopathy in Whipple's Disease
Neurol 12:65, Lampert,P.,et al, 1962
Neuro CPC of MGH
Glioblastoma Multiforme, NEJM 262:413-4161960., , 1960
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Tau Positron Emission Tomography for Predicting Dementia in Individuals with Mild Cognitive Impairment
JAMA Neurol 81:845-856, Groot,C.,et al, 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data
AJNR 41:980-986, Reith, F.,et al, 2020
Debate Sparks Over LATE, a Recently Recognized Dementia
JAMA 322:914-916, Abbasi, J., 2019
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Outcomes after Diagnosis of Mild Cognitive Impairment in a Large Autopsy Series
Ann Neurol 81:549-559, Abner, E.L.,et al, 2017
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Patients with Rosacea have Increased Risk of Dementia
Ann Neurol 79:921-928, Egeberg, A.,et al, 2016
Aphasic Variant of Alzheimer Disease
Neurol 87:1337-1343, Rogalski, E.,et al, 2016
Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population
Ann Neurol 77:301-311, Rasmussen, K.L.,et al, 2015
"Noncognitive" Symptoms of Early Alzheimer Disease
Neurol 84:617-622, Masters, M.C.,et al, 2015
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015